[Chemotherapy for malignant gliomas].
Nagane
Motoo
M
Department of Neurosurgery, Kyorin University School of Medicine, Shinkawa, Mitaka-shi, Tokyo, Japan.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001812:Blood-Brain Barrier; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000532:radiotherapy; D003131:Combined Modality Therapy; D015254:DNA Modification Methylases / Q000627:therapeutic use; D004260:DNA Repair; D045643:DNA Repair Enzymes / Q000627:therapeutic use; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D019008:Drug Resistance, Neoplasm; D005910:Glioma / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000532:radiotherapy; D006801:Humans; D009603:Nitroso Compounds / Q000627:therapeutic use; D015996:Survival Rate; D000077204:Temozolomide; D025521:Tumor Suppressor Proteins / Q000627:therapeutic use
D009603:Nitroso Compounds; D025521:Tumor Suppressor Proteins; C041148:N-(2-chloroethyl)-N-nitrosoacetamide; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide